413 related articles for article (PubMed ID: 22510338)
1. How do the top 12 pharmaceutical companies operate safety pharmacology?
Ewart L; Gallacher DJ; Gintant G; Guillon JM; Leishman D; Levesque P; McMahon N; Mylecraine L; Sanders M; Suter W; Wallis R; Valentin JP
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):66-70. PubMed ID: 22510338
[TBL] [Abstract][Full Text] [Related]
2. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
[TBL] [Abstract][Full Text] [Related]
3. Methodological innovations expand the safety pharmacology horizon.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
[TBL] [Abstract][Full Text] [Related]
5. Benchmarking safety pharmacology regulatory packages and best practice.
Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
[TBL] [Abstract][Full Text] [Related]
6. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
[TBL] [Abstract][Full Text] [Related]
7. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
8. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
Whitebread S; Hamon J; Bojanic D; Urban L
Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
[TBL] [Abstract][Full Text] [Related]
9. The nature of outsourced preclinical research--the example of chemical synthesis.
Festel GW
Expert Opin Drug Discov; 2013 Sep; 8(9):1049-55. PubMed ID: 23725522
[TBL] [Abstract][Full Text] [Related]
10. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies.
Friedrichs GS; Patmore L; Bass A
J Pharmacol Toxicol Methods; 2005; 52(1):6-11. PubMed ID: 15975833
[TBL] [Abstract][Full Text] [Related]
11. In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.
Valentin JP; Guillon JM; Jenkinson S; Kadambi V; Ravikumar P; Roberts S; Rosenbrier-Ribeiro L; Schmidt F; Armstrong D
J Pharmacol Toxicol Methods; 2018; 93():7-14. PubMed ID: 30030184
[TBL] [Abstract][Full Text] [Related]
12. Methodology used in safety pharmacology: appraisal of the state-of-the-art, the regulatory issues and new directions.
Pugsley MK
J Pharmacol Toxicol Methods; 2005; 52(1):1-5. PubMed ID: 15982903
[TBL] [Abstract][Full Text] [Related]
13. A framework to assess the translation of safety pharmacology data to humans.
Valentin JP; Bialecki R; Ewart L; Hammond T; Leishmann D; Lindgren S; Martinez V; Pollard C; Redfern W; Wallis R
J Pharmacol Toxicol Methods; 2009; 60(2):152-8. PubMed ID: 19616110
[TBL] [Abstract][Full Text] [Related]
14. Safety pharmacology investigations in toxicology studies: an industry survey.
Authier S; Vargas HM; Curtis MJ; Holbrook M; Pugsley MK
J Pharmacol Toxicol Methods; 2013; 68(1):44-51. PubMed ID: 23685201
[TBL] [Abstract][Full Text] [Related]
15. Non-clinical models: validation, study design and statistical consideration in safety pharmacology.
Pugsley MK; Towart R; Authier S; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2010; 62(1):1-3. PubMed ID: 20601022
[TBL] [Abstract][Full Text] [Related]
16. Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA).
Goto A; Abe S; Koshiba S; Yamaguchi K; Sato N; Kurahashi Y
Drug Metab Pharmacokinet; 2019 Apr; 34(2):148-154. PubMed ID: 30827921
[TBL] [Abstract][Full Text] [Related]
17. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
18. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
Gabrielsson J; Dolgos H; Gillberg PG; Bredberg U; Benthem B; Duker G
Drug Discov Today; 2009 Apr; 14(7-8):358-72. PubMed ID: 19162219
[TBL] [Abstract][Full Text] [Related]
19. Innovation in safety pharmacology testing.
Pugsley MK; Towart R; Authier S; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2011; 64(1):1-6. PubMed ID: 21640842
[TBL] [Abstract][Full Text] [Related]
20. Methods in safety pharmacology in focus.
Pugsley MK; Gallacher DJ; Towart R; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2008; 58(2):69-71. PubMed ID: 18707009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
